On Jul 19, 2021 Frontier Medicines closed a Series B round and raised $88,500,000 from ArrowMark Partners, DCVC Bio, Deep Track Capital, Deerfield, Driehaus Capital Management, DROIA, MPM Capital, RA Capital Management, Sphera Global Healthcare Fund, Woodline Partners, round led by Woodline Partners. Derek DiRocco, partner at RA Capital Management, joined Frontier’s board of directors.
About the company: Frontier Medicines is located in San Francisco, United States, North America. “Frontier Medicines is a precision medicine company that has pioneered a proprietary discovery and development platform to develop medicines against disease-causing proteins previously considered undruggable. We are deploying groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to develop medicines, starting with anti-cancer therapies.” The cancer drug developer already has a research partnership with AbbVie.
Company website: frontiermeds.com